Sun Pharma Advanced Research Company Limited investor presentation summary

Investor presentation of 31 Dec 2025, summarised by AI from the filing.

SPARC to host R&D Day on January 8, 2026, sharing strategic updates on key programs and R&D pipeline.

Key takeaways

1. R&D Day SPARC will host its R&D Day over an audio conference on Thursday, January 8, 2026, providing updates on prioritized programs and pipeline progress.
2. Call timing The conference call is scheduled at 4:00 PM IST and will be reachable through an audio dial-in.
3. Presentation access The management presentation can be accessed through the link on the date of the audio conference.
4. Company profile SPARC is a pharmaceutical company focused on improving standards of care globally through innovation in therapeutics and delivery.
5. Cost focus SPARC aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world.

Original filing on BSE

Sun Pharma Advanced Research Company Limited Q1 FY27 results

As filed: Revenue ₹39.9 cr (+299% year on year), EBITDA −₹34.0 cr, PAT −₹20.8 cr, EBITDA margin -85.2%.

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹1,853 cr (+300% year on year), EBITDA ₹1,773 cr, PAT ₹1,761 cr, EBITDA margin 95.7%. Score 100 of 100, Above trend. Revenue growth was well above the company's own trend. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +47.7% in 30 days (Nifty 500: +2.9%).
• Q3 FY26: Revenue ₹8.5 cr, EBITDA −₹56.6 cr, PAT −₹80.4 cr, EBITDA margin -670.3%. Not scored. Too small to score: quarter revenue ₹8.5 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −9.8% in 30 days (Nifty 500: −5.9%).
• Q2 FY26: Revenue ₹8.0 cr, EBITDA −₹65.0 cr, PAT −₹76.0 cr, EBITDA margin -812.5%. Not scored. Too small to score: quarter revenue ₹8.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +4.8% in 30 days (Nifty 500: −0.8%).
• Q1 FY26: Revenue ₹10.0 cr, EBITDA −₹52.0 cr, PAT −₹52.0 cr, EBITDA margin -520.0%. Not scored. Too small to score: quarter revenue ₹10.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −2.0% in 30 days (Nifty 500: +0.8%).
• Q4 FY25: Revenue ₹27.0 cr (+59% year on year), EBITDA −₹53.0 cr, PAT −₹60.0 cr, EBITDA margin -196.3%. Score 45 of 100, In line with trend. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.8% in 30 days (Nifty 500: +0.3%).
• Q3 FY25: Revenue ₹15.0 cr, EBITDA −₹73.0 cr, PAT −₹80.0 cr, EBITDA margin -486.7%. Not scored. Too small to score: quarter revenue ₹15.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
• Q2 FY25: Revenue ₹13.0 cr, EBITDA −₹103 cr, PAT −₹107 cr, EBITDA margin -792.3%. Not scored. Too small to score: quarter revenue ₹13.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Sun Pharma Advanced Research Company Limited earnings call, investor presentation and press release summaries

• Other events: Investor presentation (8 Jan 2026), Investor presentation (31 Dec 2025)